Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients

Fig. 3

Analysis of survival time in subgroups stratified by R status and the resectability by National Comprehensive Cancer Network guideline. Among patients who underwent R0 resections, a the Responder group showed a significantly better prognosis than the Non-responder group (3-year OS: 52.4 and 45.7%, P = 0.050), and an equivalent prognosis to the Normal group (59.3%, P = 0.907). On the other hand, among patients who underwent R1 resections (b) no significant differences were observed between the Responder and Normal or the Responder and Non-responder groups (P = 0.641 or P = 0.634). Among patients with resectable pancreatic adenocarcinoma (c) the Responder group showed a better prognosis, with a 3-year OS of 65.9%, than the Non-responder group, with a 3-year OS of 51.1% (P = 0.078), and a comparable value to the 3-year OS of the Normal group of 75.5% (P = 0.319). On the other hand, among patients with borderline pancreatic cancer (d), no significant differences were observed between the Responder and Normal or the Responder and Non-responder groups (P = 0.344 and P = 0.312, respectively)

Back to article page